Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05423652
Other study ID # REB22-0434
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 16, 2023
Est. completion date December 31, 2024

Study information

Verified date November 2023
Source University of Calgary
Contact Michelle Grinman, MD FRCPC MPH
Phone 403.943.3889
Email michelle.grinman@ucalgary.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single-center, two-arm, parallel, randomized controlled trial comparing enhanced daily assessments for patients with COPD and/or CHF using point of care ultrasound with PRESUNA software (POCUS-PRESUNA) versus standard care provided by home-based acute care through a tertiary acute care medical teaching hospital. The objectives are to evaluate POCUS-PRESUNA on improving patient experience, provider experience, improve healthcare utilization/costs, and to test the feasibility of incorporating longitudinal POCUS assessments in home-based acute care via remotely acquired images by non-physicians.


Description:

PRESUNA, a new medical software platform that supports clinicians in optimizing their use of POCUS for CHF and COPD patients in the community, is designed to enhance clinical decision-making and long-term monitoring of patients with CHF and COPD. The aim is to more precisely identify changes in the lungs in order to proactively treat exacerbations and confirm treatment responses. It will also enable practitioners to share information from each scan visually and in a standard format in order to track changes longitudinally. This is expected to reduce potentially avoidable hospitalizations and increase patient quality of life in the community. This study will implement the use of POCUS enhanced by PRESUNA software in the clinical practice of clinicians on a home hospital (HH) program at a tertiary teaching hospital in Calgary, Alberta. On this home hospital, patients are seen and examined either by home visiting community paramedics who consult with the physician, or in-person by physicians in the home hospital clinic space when expedited diagnostic imaging or investigations are required. Objective: To perform a randomized control trial comparing patients with COPD and/or CHF admitted to the HH who will undergo usual care versus usual care enhanced with POCUS and PRESUNA. Methods: 1. Practitioner Recruitment Home hospital clinicians will be provided information about this study in order to obtain informed consent for participation in the study. Physicians who are already POCUS experts will provide informed consent to undergo training on how to use PRESUNA software and to incorporate POCUS into their home hospital care for intervention study patients. Non-POCUS expert clinicians (community paramedics, some of the physicians and nurses) will provide informed consent to undergo group POCUS training and subsequent individual training sessions in order to enable them to become proficient at using POCUS. They will also consent to being trained on how to use PRESUNA software, as well as incorporating POCUS and PRESUNA into their home hospital care for intervention arm patients. 2. Patient Recruitment Patients admitted to HH with CHF and/or COPD will be approached to participate in the research study by the Nurse Navigator or Research Assistant. Those that provide informed consent will be randomized (1:1) to the intervention (POCUS-PRESUNA enhanced HH care) versus control group (usual HH care).


Recruitment information / eligibility

Status Recruiting
Enrollment 44
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Patient Inclusion Criteria: - 18 years of age or older - Has a provincial health care number - Functionally safe to receive HH care or have sufficient caregiving to support them at home - Stable enough to be cared for at home - stable vital signs and requiring no more than 2 visits per day - Able and willing to follow a management plan - Provides consent to receive care on HH - Diagnosis of CHF and/or COPD that requires HH care - No painful/broken ribs that could be affected by pressure applied when performing lung POCUS Patient Exclusion Criteria: - Not eligible for HH care - New unstable rib fractures - Prior history of allergy to ultrasound gel - Participant refusal to participate in research study Provider inclusion criteria - Attending clinician on the home hospital program within the next 3-6 months - Provides informed consent to participate in the study, including necessary training for the use of POCUS and/or PRESUNA Provider exclusion criteria - Not a home hospital clinician - Refuses to consent for the study / training.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Lung point of care ultrasound
Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
Other:
PRESUNA software
PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.

Locations

Country Name City State
Canada Rockyview General Hospital Calgary

Sponsors (4)

Lead Sponsor Collaborator
Michelle Grinman Alberta Boehringer Ingelheim Collaboration, Institute of Health Economics, Canada, PRESUNA

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of stay Length of stay for index Home Hospital admission From the date of admission to discharge from the index admission, assessed up to 1 year
Secondary Patient outcome - Time to resolution of infection return to baseline oxygen saturation and normalization of white blood cell count Assessed up to 24 months after infection identified
Secondary Patient outcome - time to decongestion absence of crackles and baseline oxygen saturation on lung examination Assessed up to one year after congestion identified
Secondary Patient outcome - rate of change in NT-BNP Difference between NT-BNP on admission and at time of decongestion over total number of days Change from admission to when decongestion occurred, assessed up to 12 months
Secondary Patient outcome - Admission to facility living Proportion of patients in each study arm that required admission to facility living (eg: long-term care, supportive living) after their index admission From date and time of discharge from index admission, assessed up to 12 months
Secondary Patient outcome - Escalation of care Incidence rate ratio for frequency with which patients are transferred back to the bricks and mortar hospital from the home hospital. From date of randomization until the patient is discharged from the index admission (assessed up to 12 months).
Secondary Patient outcome - Adverse events Frequency and severity of adverse events (venous thromboembolism, new infections, falls, delirium) From date of randomization until the date of first documented progression or date of death from any cause, whichever came first until the patient is discharged from the hospital (assessed up to 12 months).
Secondary Patient outcome - Mortality Date and cause of mortality of occurrence of mortality From date of randomization until the date of death, assessed up to 12 months
Secondary Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Mobility The ability to mobilize is rated by patients on a scale from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity) At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Secondary Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Activities of daily living Ability to perform activities of daily living rated by patients from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity) At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Secondary Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Pain and discomfort The intensity of pain or discomfort is rated by patients from 1 to 5 (1=none, 2= slight , 3= moderate , 4=severe, 5=extreme). At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Secondary Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Self care Ability to perform self-care rated from 1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Secondary Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Anxiety and Depression Patients rate whether they feel anxious or depressed from 1-5 (1=no, 2= slightly, 3= moderately, 4=severely, 5=extremely). At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Secondary Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Index Score The index score is computed using the EQ-5D calculator that uses the scores of the individual dimensions (mobility, self-care, activities of daily living, pain and discomfort, anxiety and depression); Scores range between 5-25 with higher scores indicating a worse outcome At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Secondary Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) Visual Analogue Scale (EQ-VAS) Participant asked to rate both verbally and visually "where [they] would put [their] health today" on a scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine) At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
Secondary Patient experience Survey measuring experience with clinical care and various technologies employed by the Home Hospital (digital remote patient monitoring, videoconferencing, as well as POCUS for the intervention arm). This survey was developed by the study team. Responses to questions were either, "yes", "yes, to some extent", "no", and "unsure". Upon discharge from the Home Hospital (up to 7 business days post-discharge)
Secondary Provider experience Surveys including experience providing care for patients on each study arm and experience with various technologies employed in the home hospital program (digital remote patient monitoring, videoconferencing, as well as POCUS and PRESUNA for the intervention arm). This survey was developed by the study team. Responses were on a Likert scale, which included "strongly disagree", "disagree", "neither agree/nor disagree", "agree" and "strongly agree" Within 1 week of being on the Hospital at Home service
Secondary Healthcare utilization cost - Diagnostic testing Cost of Diagnostic testing Between the date and time of hospital admission to up to 3 months post-discharge
Secondary Healthcare utilization - Incidence rate ratio of acute care days pre/during/post Incidence rate ratio of acute care days in the bricks and mortar hospital 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission 90 days before randomization until 90 days after index admission (assessed up to 15 months)
Secondary Healthcare utilization - Incidence rate ratio of ED/Urgent Care visits pre/during/post Incidence rate ratio of ED and urgent care visits- 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission 90 days before, during and 90 days after index admission
Secondary Cost analysis Incremental effectiveness ratio for the index admission From date of admission until the date of discharge from the index admission, assessed up to 12 months").
Secondary Cost analysis Incremental effectiveness ratio for healthcare utilization post-discharge From date of discharge from index admission, assessed up to 90 days.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A